

**Present:**

Dr J Dent	Colorectal NSSG Representative
Dr D Jackson	Gynae NSSG Representative
Mr P Trueman	Health Economist (York Health Economics Consortium)
Mr G Fell (Chair)	NHS Bradford & Airedale
Mrs S Frier	NHS Leeds
Mr J Hancock	NHS North Yorkshire and York
Mr P McManus	Yorkshire and The Humber SCG & PCT Collaborative
Mr D Thomson	Yorkshire Cancer Network

**Apologies**

Ms M Allinson, Mrs J Cawtheray, Professor D Dodwell, Mr S Duffy, Ms A Johnson, Dr R Johnson, Mrs S Keir, Dr T Perren, Mr C Sloane, Dr M Snee

<b>1. Welcome and Apologies</b>			
Log No	Action	Lead(s)	Deadline
39	G Fell welcomed the group and apologies were noted. Introductions were made around the table.	N/A	N/A
<b>2. Action Log from the last meeting</b>			
Log No	Action	Lead(s)	Deadline
40	The action log from the meeting held on 10th June 2009 was agreed as an accurate record.	N/A	N/A
<b>3. Matters arising</b>			
Log No	Action	Lead(s)	Deadline
41	S Frier requested feedback from Log No. 18; whom is the deciding Commissioner when making recommendations to the YCN Management Board? G Fell clarified that it is at his understanding the Gateway Group will make a recommendation to the YCN Management Board and that the Specialist Commissioning Group makes the final decision with consensus across the 3 Networks.  It was highlighted that the YCN Board aspect to the process could be removed as commissioning representation is the same as the Gateway Group's.  B Tinkler to have discussions with J Hancock, YCN Commissioning Group Chair regarding removing the YCN Management Board involvement from the process.	B Tinkler	30/09/2009
42	To streamline SCG involvement the Tri-Network are to be continually informed throughout the process.	P McManus	30/09/2009
43	D Thomson, D Jackson, G Fell and P Trueman to meet regularly pre and post YCN Gateway Group meetings  S Thornborow to make arrangements.	S Thornborow	30/09/2009

<b>3. Matters arising</b>			
Log No	Action	Lead(s)	Deadline
<b>44</b>	<p>D Jackson gave an update from Log No. 18 (previous Log No. 5). D Jackson has had discussions informally with Matt Walsh and Annabel Johnson regarding excess treatment costs. The group agreed the unresolved issue needs to be formally discussed at the YCN Commissioning Group meeting in September.</p> <p>S Thornborow to add 'Sunitinub Post Trial' to YCN Commissioning Group agenda.</p> <p>S Frier and G Fox to ensure A Johnson and a representative from Leeds PCT are present at the meeting and are appropriately briefed before hand. D Jackson to be invited to the meeting to give clinical perspective. As well as Dr Janet Brown who raised the issue initially.</p>	S Frier & G Fox	26/08/2009
<b>3.1 Launch event</b>			
Log No	Action	Lead(s)	Deadline
<b>45</b>	<p>D Thomson discussed the draft programme. Representatives present agreed to the programme.</p> <p>It was highlighted that adding an explanation of the Gateway process would be appropriate in the introduction by G Fell.</p> <p>J Dent agreed to also discuss Upper GI.</p> <p>D Thomson and D Jackson to produce a template slide for the horizon scanning presentations.</p> <p>D Thomson is prepared to provide any support to those involved in presenting.</p>	D Jackson & D Thomson	02/09/2009
<b>3.2 Horizon scanning 2010/11</b>			
Log No	Action	Lead(s)	Deadline
<b>46</b>	D Thomson to request expected patient numbers for YCN from the top 5 groups to broaden the data. To be tabled at the next meeting.	D Thomson	30/09/2009
<b>3.3 Decision making locally/regionally</b>			
Log No	Action	Lead(s)	Deadline
<b>47</b>	As discussed previously.	N/A	N/A
<b>4. Proposed additions to work programme</b>			
<b>4.1 Gefitinib in NSCLC</b>			
Log No	Action	Lead(s)	Deadline
<b>48</b>	<p>D Thomson discussed the nomination by the YCN Lung Group. Gefitinib will be commercially available in September 2009.</p> <p>The group queried whether the Gefitinib should be added to the work programme due to a possibility of it not being cost effective without the patient access scheme and both PCT and Trusts collectively not having an agreed policy on the benefits or otherwise of access schemes.</p> <p>It was agreed Gefitinib in NSCLC would be added to the work programme with Trusts being asked to identify any issues with the 'access scheme'.</p> <p>D Thomson to prepare documentation for the next meeting on 30th September.</p>	D Thomson	23/09/2009

<b>5. Clinical submissions for discussion</b>			
<b>5.1 Everolimus in RCC</b>			
Log No	Action	Lead(s)	Deadline
<b>49</b>	<p>D Thomson informed the group that the clinical and safety documents have been written and signed off by the clinician Dr Satinder Jagdev.</p> <p>It was highlighted that Everolimus will cause increased activity, PCT representatives requested that the cost estimation of the increased activity be built into both the appraisal of cost effectiveness and the budget impact. D Thomson noted that the tariff cost 2010/2011 is the information used currently.</p> <p>It is anticipated that there will be a high demand for Everolimus in RCC.</p> <p>The group agreed for the submission to be reviewed by P Trueman and for the results to be discussed at the next meeting.</p>	P Trueman	23/09/2009
<b>6. Topics for decision</b>			
<b>6.1 Bevacizumab in MBC - DTC decisions</b>			
Log No	Action	Lead(s)	Deadline
<b>50</b>	D Thomson discussed the tabled clinical paper and informed the group that no DTC's have responded with comments. During the meeting it was highlighted that Calderdale and Huddersfield have approved the clinical data, and LTHT had deferred until their next meeting.	N/A	N/A
<b>6.2 Bevacizumab in MBC - Budget impact</b>			
Log No	Action	Lead(s)	Deadline
<b>51</b>	Budget impact model was discussed.	N/A	N/A
<b>6.3 Bevacizumab in MBC - Health economics</b>			
Log No	Action	Lead(s)	Deadline
<b>52</b>	<p>P Trueman informed the group that Roche had not been forthcoming with data. The Health Economics Consortium assessment of available data is that Bevacizumab is unlikely to be cost effective based on the evidence available.</p> <p>Given that the key clinicians were not at the meeting, the group agreed that D Dodwell and T Perren need to have the opportunity to comment before a decision is taken by the group on this drug. Trusts should be asked once again to consider this case at their own DTC and should be asked to note that the decision will not be delayed further than the next meeting when the views of D Dodwell and T Perren will be clearer.</p> <p>It was agreed the DTCs would be given another opportunity to comment with a view to a final decision at the next meeting.</p>	D Thomson	30/09/2009
<b>53</b>	The issue of representation was raised. For the YCN Gateway Group process to function representation from PCTs and Clinicians need to be present. D Jackson to feedback to clinical colleagues and G Fell to raise with commissioning colleagues.	D Dodwell & D Jackson	30/09/2009
<b>54</b>	The group extended the discussion to voting rights and queried why clinicians are not part of the vote. G Fell agreed to raise this issue with the YCN Management Board in form of a letter.	G Fell	30/09/2009

<b>7. Update on topics underway/completed</b>			
<b>7.1 Topotecan in SCLC</b>			
Log No	Action	Lead(s)	Deadline
<b>55</b>	<p>P McManus informed the group that the submission had been submitted to North Trent and Humber and Yorkshire Coast Cancer Networks for decision.</p> <p>Yorkshire and Humber Coast have agreed. Still awaiting North Trent's decision. North Trent meet in September one week prior to SCG so a decision is likely in September.</p> <p>P McManus to inform D Thomson of the outcome.</p>	P McManus	30/09/2009
<b>7.2 Trastuzumab beyond progression</b>			
Log No	Action	Lead(s)	Deadline
<b>56</b>	<p>D Thomson gave an update on Trastuzumab, which is a case in conjunction with London Cancer New Drug Group (LCNDG). LCNDG continue to develop their review with input from D Dodwell and T Perren but timescales are unclear.</p> <p>P Trueman informed the group that the draft health economics review was now available. T Perren and D Dodwell to provide comments before sharing with LCNDG. To review at the next meeting.</p>	P Trueman & D Thomson	30/09/2009
<b>7.3 Azacitadine in MOS</b>			
Log No	Action	Lead(s)	Deadline
<b>57</b>	D Thomson to liaise with David Bowen. NICE appraisal still anticipated for November 2009.	D Thomson	30/09/2009

**Date of Next Meeting(s)**

Wednesday 30th September 2009 2:00pm  
 Committee Room 1, Trust HQ, Ground Floor, St James's University Hospital

Friday 16th October 2009 9:00am  
 Weetwood Hall Conference Centre & Hotel, Leeds, LS16 5PS []

Wednesday 25th November 2009 2:00pm  
 Committee Room 1, Trust HQ, Ground Floor, St James's University Hospital

Wednesday 20th January 2010 2:00pm  
 Committee Room 1, Trust HQ, Ground Floor, St James's University Hospital